Optimizing the prescription isodose level in stereotactic volumetric-modulated arc radiotherapy of lung lesions as a potential for dose de-escalation

Mark Chan1,2, Matthew Wong3, Ronnie Leung3, Steven Cheung3 and Oliver Blanck1,4*

Abstract

Background: To derive and exploit the optimal prescription isodose level (PIL) in inverse optimization of volumetric modulated arc radiotherapy (VMAT) as a potential approach to dose de-escalation in stereotactic body radiotherapy for non–small cell lung carcinomas (NSCLC).

Methods: For ten patients, inverse Monte Carlo dose optimization was performed to cover 95% PTV by varying prescription isodose lines (PIL) at 60 to 80% and reference 85%. Subsequently, these were re-normalized to the median gross tumor volume dose (GTV–based prescription) to assess the impacts of PTV and normal tissue dose reduction.

Results: With PTV–based prescription, GTV mean dose was much higher with the optimized PIL at 60% with significant reduction of normal lung receiving 30 to 10 Gy \( (V_{30-10Gy}) \), and observable but insignificant dose reduction to spinal cord, esophagus, ribs, and others compared with 85% PIL. Mean doses to the normal lung between PTV and GTV was higher with 60–70% PIL than 85%. The dose gradient index was 5.0 ± 1.1 and 6.1 ± 1.4 for 60 and 85% PIL \( (p < 0.05) \), respectively. Compared with the reference 85% PIL plan using PTV–base prescription, significant decreases of all normal tissue doses were observed with 60% and 70% PIL by GTV–based prescription. Yet, the resulting biological effective (BED) mean doses of PTV remain sufficiently high, ranging 104.2 to 116.9 Gy \( \alpha/\beta = 10 \).

Conclusions: Optimizing the PIL with VMAT has notable advantage of improving the dosimetric quality of lung SBRT and offers the potential of dose de-escalation for surrounding tissues while increasing the GTV dose simultaneously. The clinical implication of re-normalizing plans from PTV–prescription at 60–70% to the GTV median dose requires further investigations.

Background

Optimization of stereotactic body radiotherapy (SBRT) plan quality is crucial to minimize normal tissue dose and hence toxicities for inoperable early stage non–small–cell lung cancer (NSCLC). In lung SBRT small photon fields are widely used, which are known to introduce significant lateral electronic disequilibrium (LED) in heterogeneous tissue caused by out–scattering electrons not being compensated by in–scattering electrons \[1\]. Using the LED phenomenon for optimizing lung SBRT (LED–SBRT), which is based on the differential reductions of lung and tumor doses caused by the LED in order to steepen the dose gradients and thereby increasing the dose within the tumor while reducing the dose in the normal lung, has been recently proposed by Disher et al. \[1\]. However, in order for LED–SBRT to be robust against dosimetric errors, Monte Carlo (MC) simulation techniques \[2\] must be employed to accurately model the particle transport.

Besides direct MC simulation, the LED phenomenon was also investigated implicitly through the relationship with the prescription isodose line (PIL) by comparing the dose results from type–A pencil beam (PB), which cannot model the LED, and type–B MC based dose

* Correspondence: blanck@saphir-rc.com
1University Medical Center Schleswig–Holstein, Campus Kiel, Department for Radiation Oncology, Arnold–Heller–Straße 3, Haus 50, Karl–Lennert–Krebscentrum Nord, 24105 Kiel, Germany
4Saphir Radiosurgery Center Northern Germany, Güstrow, Germany

Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
calculations [3]. Using multiple dynamic conformal arcs (DCA), Oku et al. showed a clear dependence of the PIL on the dosimetric plan quality [4]. They found higher lung dose and lower dose conformity at 50% downwards to 20% PIL after the optimal improvement at 60% PIL with respect to the reference of 80% PIL. Similar results of optimal PIL at ~60–70% and much lower at ~40–50% were found for forward planned linac–based and inverse planned robotic–based SBRT lung treatments, respectively [5].

The clinical implication of lowering the PIL to 60% vs. 80% PIL in 5–fraction lung SBRT was initially studied by Takeda et al., also using DCA techniques [6]. After 6 months post–SBRT, they found no local recurrences and only a limited number of incidents of radiation pneumonitis ≥ Grade 2 (1 out of 15 patients) with lower PIL. Furthermore, Guckenberger et al. found in their retrospective large–scale multi–center analysis with low PIL (<80%) a significant higher freedom from local progression as compared to higher PIL (86.8% vs. 69.1%, \( p = 0.005 \)), again with lower toxicity for lower PIL [7]. Further evidence of the clinical effects of varying PIL was supported by a number of recent published series from European and Japanese SBRT working groups that was supported by a number of recent published series. Further evidence of the clinical effects of varying PIL was supported by a number of recent published series from European and Japanese SBRT working groups that demonstrated the iso–effectiveness of SBRT treatments between those prescribing the biological effective dose (BED) \( > 100 \text{ Gy}_{10} (\alpha / \beta = 10 \text{ Gy for NSCLC}) \) to the isocenter, to the PTV periphery with 95% coverage \( (D_{95\%}) \), and to the GTV mean or median dose [8–13].

Despite the similar local control rates reported based on different prescription concepts, the inconsistency of the conventional PTV prescription concept has been well acknowledged in the latest published International Commission on Radiation Units and Measurements (ICRU) report 91 [14], pointing at increased variability of the internal GTV dose for lung SBRT. Although the report hinted at a possible solution by using a GTV–based prescription and a few other studies [15–17] concomitantly showed more consistent GTV dose when re–normalizing or prescribing the treatment dose to the GTV mean or median dose or \( D_{99\%} \), the implications of such GTV–based re–normalization/re–prescription with respect to the PIL in the conventional PTV prescription concept has never been studied.

In this work, we focused on the technical feasibility of enhancing the dosimetric quality of inverse VMAT optimization by assessing the optimal PIL and with that the potential for dose de–escalation. Further on the hypothesis that the potential dependence of plan quality on the PIL is related to the LED, retrospective PB recalculation were performed for all direct MC–optimized VMAT plans to assess the relationship of the PIL with the dosimetric changes. Ultimately, we tried to investigate the GTV–based re–normalization / re–prescription concept with respect to the PIL for VMAT LED–SBRT.

**Methods**

**Patient selections and 4DCT imaging**

This retrospective dosimetric study, approved by the local clinical and research ethics committee, included ten patients with primary NSCLC. The tumor size ranged from 11.7 to 82.6 cm\(^3\). Each patient had a four–dimensional computed tomography (4DCT) scan that was sorted into ten 3DCT image datasets with equal time share. Each 3DCT had a slice thickness of 2 mm in the axial direction. We determined the mid–ventilation (MidV) phase from the 4DCT series for treatment planning as described previously [18].

**Treatment planning and dose prescription**

The GTV was contoured based on standard international guidelines and was expanded according to the mid–ventilation PTV concept [19]. Treatment prescription was 54 Gy in 3 fractions regardless of tumor location and size.

Dose constraints for the target and other OARs were defined following the guidelines in the ROSEL [20] and RTOG 0236 [21, 22] trials. It was demanded that dose to 95% of the PTV (PTV \( D_{95\%} \)) and 98% of the GTV (GTV \( D_{98\%} \)) must at least receive the prescription dose. Also the dose to 98% of PTV (PTV \( D_{98\%} \)) had to exceed 90% of the prescription dose. Furthermore, we limited the maximum dose in the PTV to be within 167% of the prescription dose despite the fact that the optimal dose gradient that may occur at as low as ~30% PIL [1] because very limited clinical trials reporting safety and toxicities with PIL <60% were available. Dose limits of chest wall and rib may be exceeded in case of large overlap with the PTV, as suggested in the RTOG 0915 trial [23].

**VMAT–based PIL–SBRT optimization**

For all patients, volumetric–modulated arc radiotherapy (VMAT) optimizations of lung SBRT plans were performed using the Monaco treatment planning system (TPS, v.5.0, Elekta, Sweden) for the Elekta Agility™ linear accelerator (linac) equipped with a multileaf collimator (MLC) with 160 leaf pairs of 5 mm width. The VMAT plans consisted of two either full or partial 6 Mega–volt–age (MV) coplanar arcs, depending on the location of the tumor to avoid direct beam entrance to the contralateral lung and other central organs at risk (OAR).

For each patient, a reference plan at 85% PIL was generated while keeping the dose constraints of the OARs as low as reasonably achievable (ALARA). Unlike the strategy with DCA, where the beam penumbra margin is manually adjusted to achieve varying levels of PIL, the MLC shapes in VMAT are completely controlled by the optimizer in achieving the dose–volume histogram (DVH) objectives. To implicitly manipulate the PIL in the inverse optimization process, we varied the maximum dose to the
PTV and the GTV together with demanding higher minimum dose or DVH constraints to the GTV to achieve a lower or higher PIL. Dose constraints of all other OARs were kept unchanged in all inverse optimized plans for each patient to minimize the planner-related bias on the final plan quality as much as possible.

Using these optimization strategies, four plans were generated, with the reference corresponding to 85% PIL, and the other three corresponding to 80%, 70% and 60% PILs. All VMAT plans were directly optimized by Monte Carlo (MC) simulation techniques [24] and the final dose distributions were calculated to dose to medium in medium \((D_{nn,m})\) using 2 mm dose grid and 0.5% relative statistical uncertainty.

**Plan evaluation and statistical analysis**

Dosimetric parameters of the reference plan and the PIL-optimized plans as defined in ROSEL [20] and RTOG 0236 [21, 22] trial protocols were compared, which included the normalized volume received at least 5 to 30 Gy \((V_{5–30Gy})\) by the normal lungs, the absolute volume received at least 30 Gy and 100% of the prescription dose by the chest wall, dose to 1% \(D_{1\%}\) of the cord, trachea, bronchus, esophagus and heart. The near-minimum dose \(D_{98\%}\), to PTV and GTV mean dose \(D_{mean}\) were also included. The target dose conformity was assessed using the Paddick’s conformity index [25]. The dose gradient was evaluated by the ratio of 50% prescription isodose volume to the PTV \((R_{50\%})\), and its constraint was adapted according to Xiao et al. [22] based on their retrospective re-evaluation of the dosimetric effects of heterogeneity corrections for the case submissions in the RTOG 0236 trial [21].

Further on the hypothesis that the potential dependence of plan quality on the PIL is related to the LED, all the direct MC-optimized plans were re-calculated by a PB dose engine developed by Jelen et al. [26] The resulting difference was evaluated based on mean dose and \(D_{2\%}\) of the PTV border \((i.e.,\ PTV\ minus\ GTV)\) because it coincided with the low density tissue and the field edge where the LED was likely most severe.

Following the GTV-based prescription approach described by Bibault et al. [8] and Muiira et al. [16], all original PTV-based prescription plans of varying PILs were re-normalized such that the GTV \(D_{50\%}\) equals 54 Gy. The resultant GTV-prescribed plans at the optimal 60% and 70% PILs were compared to the reference PTV-based prescription plans at 85% PIL to study the implications of varying PILs in different prescription concepts.

Statistical comparisons of various plan quality parameters between plans of different PILs were performed by Freidman’s test. When statistical significance was found, further post-hoc test by the default Tukey’s honest significant difference criterion was performed using the Matlab statistics toolbox (MathWorks, Natick, MA). Further, Wilcoxon’s test was performed to assess the significance of normal tissue dose reductions achieved with GTV-based prescription compared with the reference 85% PIL plan with PTV-based prescription. Test results were considered statistically significant at \(p < 0.05\).

**Results**

**VMAT-based PIL-SBRT optimization**

GTV mean doses \(\langle D_{mean}\rangle\) increased from 85% PIL by 6.1 ± 2.2% \((mean \pm 1\ standard\ deviation\ (SD))\), 19.2 ± 3.3%, and 35.0 ± 5.5% with decreasing PILs to 80%, 70% and 60%, respectively \((p < 0.01)\). The mean near-minimum dose \(D_{98\%}\) of PTV showed an observable but insignificant descending trend with decreasing PIL and the differences among PILs of individual patients were within 2%.

Variations of the normal lung volumes receiving high to low doses of 30 Gy to 5 Gy \((i.e.,\ V_{30Gy}\ to\ V_{5Gy})\) are shown in Fig. 1. Largest lung sparing was observed in seven out of ten plans at 60% PIL, with up to 23.2% and 19.9% reduction in \(V_{30Gy}\) to \(V_{20Gy}\) \((p < 0.05)\), and at 70% PIL eight and nine out of ten plans produced better \(V_{30Gy}\) and \(V_{20Gy}\) \((p < 0.05)\) compared to the reference plans at 85% PIL, respectively. The absolute changes of the mean \(V_{30Gy}\) and \(V_{20Gy}\) were however negligible, amounting to 0.9% and 1.4% for 60% PIL plans, and 0.9% to 1.3% for 70% PIL plans, respectively. For the low dose lung volume \((V_{10Gy}\ and\ V_{5Gy})\), three plans showed lowest \(V_{10Gy}\) and \(V_{5Gy}\) at the 60% PIL while six and five plans showed lowest \(V_{10Gy}\) and \(V_{5Gy}\) at the 70% PIL, respectively. Figure 2 shows \(V_{5Gy}\) and the mean dose to the normal lung included in the PTV \((i.e.,\ PTV\ minus\ GTV)\). Results of dose constraint parameters of other OARs were given in Table 1. Statistical tests showed significant differences between the reference 85% and other PILs mainly for dose metrics of target volumes and normal lung. The potential of PIL–VMAT to increase the tumor dose while keeping the critical organ doses was illustrated in Fig. 3.

Considering dose received by the chest wall and ribs, the 60% PIL resulted in the lowest averaged \(V_{30Gy}\). However, the chest wall volume receiving dose ≥100% of the prescription dose is higher with the 60% PIL \((n = 4)\) by 0.3 to 12.8 cm\(^3\) than with the 85% reference PIL in 4 lesions that abutted to the chest wall.

Both the target dose conformity (nCI) and the dose gradient \((R_{50\%})\) were found to be comparable between plans at different PILs \((p > 0.05)\). Nonetheless, the \(R_{50\%}\) dose constraint criterion, suggested by Xiao et al. [22], was met by the reference 85% PIL in only one patient, by 80% PIL in two patients, by 70% PIL in four patients and by 60% PIL in five patients (Fig. 4). The
dose gradient was statistically better with 60% compared to the reference 85% PIL \((p < 0.05)\).

**Correlation between PIL and LED**

Figure 5 shows the difference between the MC optimized and PB re-calculated plans in \(D_{\text{mean}}\) and \(D_{98\%}\) of the PTV minus GTV border zone at varying PILs. The MC results predicted lower \(D_{\text{mean}}\) and \(D_{98\%}\) than PB, and the differences increased with decreasing PILs, indicating increasing magnitude of LED. It is noteworthy thought that significant dependence of PIL was observed only for \(D_{\text{mean}}\) in the border zone.

**GTV–based prescription with varying PIL**

The effect of inverse–optimization with GTV–based prescription concepts was clearly demonstrated in Fig. 6. After re–normalizing the prescription such that 50% of the GTV received 54 Gy, the peripheral dose of the PTV in terms of \(D_{95\%}\) remained reasonably high, ranging from 33.5 to 36.1 Gy at 60% IDL, and 38.3 to 39.8 Gy at 70% IDL, respectively. Normal tissue doses were further decreased with decreasing PIL (Table 2). When compared with the reference 85% PIL plan employing PTV–based prescription, significant decreases of all normal tissue doses were achieved with 60% and 70% PIL by GTV–based prescription.
Discussion
This study demonstrated the technical feasibility of optimizing the PIL through its implicit relation with the lateral electronic disequilibrium (LED) to increase the dose gradient outside the target and hence improving the overall dosimetric quality in VMAT-based SBRT planning. This implicit relation was initially investigated in terms of the PTV dose differences between the PB and the MC dose calculation results for DCA-based lung SBRT [3]. This study followed the same methodology to understand the hypothesized LED origin of the dosimetric improvement. However, following the suggestion by Dish et al. [1] that the LED phenomenon can also be exploited in inverse optimization, our results were the first to show the dependence of PIL on LED for VMAT-type lung SBRT.

Using a reverse operation to re-calculate the type–B MC optimized dose plans with the type–A PB algorithms, as opposed to Zheng et al. [3] who re-calculated the PB–optimized plans by the MC algorithms, we found significant increase of (negative) dose differences of mean dose in the low density lung tissue embedded in the PTV (i.e., PTV minus GTV) with decreasing PIL plans indicative of increased magnitude of LED at lower PIL. The net negative dose difference can be explained by the increased fluence using type–B algorithms at 60% PIL in striving to compensate the LED deficiency at the low density tissue dominant field edge. The increased fluence led to increased overall dose deposition that was assumed by the type–A PB algorithms. The D2% of the PTV border zone also showed similar trends of increasing (negative) dose differences with decreasing PIL despite insignificant statistical differences.

Unlike forward planning with DCA techniques, the advantage of inversely optimized VMAT is that the optimal MLC aperture relative to the tumor size can be solved through an intuitive adjustment of optimization parameters that are directly related to the clinical goals. Given the set of clinical goals, the optimizer would implicitly determine the optimal extent of LED adjusting for the photon beam energy as well as the variation of lung density between patients, avoiding the manual iteration of changing mostly the isotropic MLC margin to arrive at the desired PIL level, thus improving the planning efficiency. The direct incorporation of Monte Carlo dose engines further ensured that the dose distribution was robust against dosimetric errors caused by LED. Furthermore, this optimization approach is quite simple as we aimed at optimization of the PIL by adjusting the maximum and minimum dose (volume) to the target and the constraints of several dose controlling shell structures around the PTV.

Table 1 Summary of the mean and one standard deviation of the dosimetric parameters obtained with PTV–based prescription

| Parameter                        | 85% PIL          | 80% PIL          | 70% PIL          | 60% PIL          |
|----------------------------------|------------------|------------------|------------------|------------------|
| GTV Dmean (Gy)                   | 62.4 ± 1.5       | 66.2 ± 1.0       | 74.4 ± 1.1       | 84.2 ± 2.3       |
| PTV Dmean (Gy)                   | 58.7 ± 0.9       | 60.6 ± 0.7       | 63.9 ± 0.8       | 67.3 ± 1.7       |
| PTV D2%a (Gy)                    | 53.6 ± 1.7       | 53.1 ± 0.2       | 52.9 ± 0.2       | 52.6 ± 0.4       |
| Spinal cord D1% (Gy)             | 9.1 ± 2.9        | 10.0 ± 3.9       | 9.7 ± 3.8        | 10.2 ± 3.5       |
| Esophagus D1% (Gy)               | 9.4 ± 3.6        | 9.6 ± 4.9        | 9.5 ± 5.2        | 9.6 ± 5.2        |
| Bronchus D1% (Gy)                | 13.6 ± 7.6       | 13.2 ± 7.6       | 12.6 ± 7.2       | 12.0 ± 7.2       |
| Trachea D1% (Gy)                 | 5.3 ± 7.1        | 5.6 ± 7.4        | 5.1 ± 6.9        | 5.3 ± 7.3        |
| Chest wall/Rib V30Gy (cc)        | 42.0 ± 35.7      | 34.7 ± 19.0      | 33.1 ± 22.1      | 30.2 ± 20.5      |
| Heart D1% (Gy)                   | 10.7 ± 9.4       | 10.5 ± 9.3       | 10.0 ± 9.0       | 9.8 ± 8.7        |
| PTV minus GTV D95% (Gy)          | 57.6 ± 0.7       | 59.2 ± 0.4       | 61.4 ± 0.8       | 63.5 ± 1.2       |
| PTV minus GTV V10Gy (%)          | 34.5 ± 16.4      | 34.3 ± 16.2      | 34.2 ± 16.2      | 34.0 ± 15.9      |
| Normal Lung MLD (Gy)             | 5.0 ± 1.7        | 4.7 ± 1.4        | 4.6 ± 1.3        | 4.6 ± 1.4        |
| Normal Lung V10Gy (%)            | 4.9 ± 2.8        | 4.5 ± 2.0        | 4.1 ± 1.9        | 4.0 ± 1.8        |
| Normal Lung V15Gy (%)            | 8.4 ± 3.5        | 7.4 ± 3.0        | 7.1 ± 2.9        | 7.0 ± 2.9        |
| Normal Lung V20Gy (%)            | 13.9 ± 4.9       | 13.0 ± 4.1       | 12.6 ± 3.6       | 12.5 ± 3.8       |
| Normal Lung V25Gy (%)            | 19.5 ± 4.9       | 19.2 ± 4.4       | 18.9 ± 4.2       | 18.8 ± 4.2       |
| MU                               | 4717 ± 994       | 4333 ± 868       | 4615 ± 1013      | 5011 ± 1031      |
| nCI                              | 1.08 ± 0.03      | 1.07 ± 0.02      | 1.07 ± 0.01      | 1.07 ± 0.01      |
| R50%                            | 6.11 ± 1.42      | 5.73 ± 1.67      | 5.11 ± 1.26      | 5.00 ± 1.07      |

Abbreviations: GTV gross target volume, PTV planning target volume, Dmean mean dose, Dp%, dose to p percent volume of the organ, Vp%, percent volume of the organ receiving at least p Gy, MLD mean lung dose, nCI target dose conformity index, R50% dose gradient index, PIL prescription isodose line relative to the maximum dose. *Significant difference from the reference 85% PIL.
**Fig. 3** Example dose distributions achieved with varying PIL–optimized VMAT plans in the axial plane and the dose–volume histograms (DVH) of selected organs. The PILs are displayed with 100% corresponding to the treatment dose of 54 Gy. Inlet shows the magnified ipsilateral lung DVH.

**Fig. 4** The dose gradient index $R_{50\%}$ for individual lesions sorted to size. Values of $R_{50\%}$ suggested by Xiao et al. [22] are also given.
Using this inverse optimization approach, the optimal PIL showing the most rapid dose falloff, which is significantly system design and planning technique dependent, was found to be between 60% and 70%. These results were consistent with previous reports by Oku et al. [4] showing best plan at 60% PIL. Despite the theoretical benefits of lower PIL than 60%, the associated toxicity profiles and local control remain largely unknown because it produced “hot spot” in the target beyond the acceptable range by most trial protocol [20, 21, 27] and therefore very limited clinical data are available. With the optimized PILs at 60% to 70% in present study, the GTV mean dose almost doubled in comparison to the reference 85% PIL without increasing lung dose, although the dose between the PTV and GTV was on average higher at 70% and 60% PIL by 6% and 10%, respectively. Considering this fact, it may be of genuine concern that the normal tissues embedded in this region, i.e. the non-tumorous margin region where motion and system inaccuracies are compensated for, receive higher doses. Given the treatment prescription of 54 Gy in 3 fractions delivered in 2 weeks for this study, 95% of the PTV will receive at least a biological effective dose (BED) of 151 Gy\textsubscript{10}, which is likely high enough to sterilize not just the tumor cells but also all other normal tissue cells as well. Yet, the increased chance of developing high grade radiation pneumonitis or fibrosis inside this small volume between GTV and PTV may be small as incidents of radiation pneumonitis or fibrosis are generally correlated with mean lung dose or low dose lung volume which were not
increased at the lower 70–60% PIL [28]. Such assumption also has support from the recent DEGRO guidelines published by the German SBRT working group for early stage NSCLC which recommended a maximum dose of 150% to the PTV (i.e., ~ 65% PIL) based on the clinical evidences from a large–scale multi–center study [9].

Furthermore, this study clearly demonstrated that besides lung doses at optimized PIL as low as 60% doses to other serial OARs such as esophagus, heart, bronchus and trachea, major vessels, and spinal cord did not increase even for central tumors because the optimizer would automatically determine the set of anisotropic MLC margins variable with the gantry angle to achieve the specified dose constraints. This is generally impractical and labor–intensive in forward planning with DCA techniques. One of the exceptions could be tumors having the PTV overlapped with the chest walls. Nevertheless, this problem can be partly addressed by imposing more stringent dose–volume constraints on the chest wall and rib structures to push away the high dose. Also, the plan quality metric of the target dose conformity showed no statistical differences between different PILs. The dose gradient index was better for plans with 60% PIL than 80 and 85% PIL ($p < 0.05$) and was comparable between 60 and 70% PIL plans. The monitor units were found to increase with decreasing PIL in a linear manner likely resulting in minimally increased treatment time.

The additional advantage that comes along with optimized PIL at ~ 60 to 70% is the potential of further margin reduction. In this study, the mid–ventilation PTV was based on the van Herk’s margin recipe and calculated assuming a reference 85% PIL. The theoretical margin may be decreased by 1 to 2 mm from 85 to 60% PIL for our patient cohort whose observed motion was up to 2 cm, mainly due to the smaller β value of the inverse cumulative standard normal distributions at the prescribed PTV minimum dose level [19]. This margin reduction, although small, may leverage the dosimetric benefits of inverse optimization in VMAT even further, though we acknowledge that further studies are required in this regard and a discussion if the van Herk’s margin recipe can be used for inhomogeneous dose distributions is beyond the scope of this work.

Clinically, a BED of 100 Gy$_{10}$, assuming an $\alpha / \beta$ ratio of 10 Gy, has been universally recognized as the approximate threshold dose to achieve adequate local control in early stage NSCLC, however, only based on a prescription to the PTV periphery [7, 29, 30] and with unclear PIL. On the other hand, Guckenberger et al. [7] recently hinted at lower PIL (< 80%) being significantly superior in local control in their data (86.8% vs. 69.1%, $p = 0.005$). Recently, the same retrospective large–scale multi–center study have reported on local control being also significantly dependent of the maximum isocenter dose [9, 10] which strongly supports our investigation of decreasing the PIL through inverse VMAT optimization and with that increasing the GTV doses. Following that concept and going one step further, a PTV prescription

| Table 2 Summary of the mean and one standard deviation of the dosimetric parameters obtained with GTV–based prescription |
|-------------------|-------------------|-------------------|-------------------|-------------------|
|                    | 85% PIL            | 80% PIL            | 70% PIL            | 60% PIL            |
| GTV $D_{\text{mean}}$ (Gy) | 54.0 ± 0.1         | 53.9 ± 0.1         | 53.6 ± 0.2         | 54.0 ± 1.2         |
| PTV $D_{\text{mean}}$ (Gy)  | 50.7 ± 0.6         | 49.3 ± 0.7         | 46.1 ± 0.9         | 42.9 ± 1.1         |
| PTV $D_{98\%}$ (Gy)       | 45.9 ± 1.2         | 43.2 ± 0.8         | 38.2 ± 0.5         | 33.6 ± 1.1         |
| PTV $D_{95\%}$ (Gy)       | 46.7 ± 1.1         | 43.9 ± 0.7         | 39.0 ± 0.4         | 34.4 ± 0.9         |
| Spinal cord $D_{95\%}$ (Gy)| 7.9 ± 2.6          | 8.1 ± 3.2          | 7.0 ± 2.7          | 6.5 ± 2.2          |
| Esophagus $D_{95\%}$ (Gy) | 8.2 ± 3.0          | 7.8 ± 4.1          | 6.9 ± 3.8          | 6.1 ± 3.3          |
| Bronchus $D_{95\%}$ (Gy)  | 11.8 ± 6.6         | 10.9 ± 6.2         | 9.1 ± 5.2          | 7.6 ± 4.5          |
| Trachea $D_{95\%}$ (Gy)   | 4.6 ± 6.1          | 4.5 ± 6.1          | 3.7 ± 5.0          | 3.4 ± 4.6          |
| Chest wall/Rib $V_{\text{MLD}}$ (cc) | 298 ± 27.3        | 18.1 ± 16.3        | 12.4 ± 12.4        | 6.3 ± 5.5          |
| Heart $D_{95\%}$ (Gy)     | 9.2 ± 8.3          | 8.5 ± 7.5          | 7.2 ± 6.5          | 6.3 ± 5.5          |
| PTV minus GTV $D_{95\%}$ (Gy) | 49.8 ± 0.8        | 48.2 ± 0.6         | 44.3 ± 0.6         | 40.5 ± 0.6         |
| PTV minus GTV $V_{\text{5Gy}}$ (%) | 1.0 ± 1.8         | 1.3 ± 1.5          | 0.4 ± 0.5          | 0.1 ± 0.1          |
| Normal Lung MLD (Gy)      | 4.4 ± 1.6          | 4.0 ± 1.4          | 3.3 ± 1.0          | 2.9 ± 0.9          |
| Normal Lung $V_{\text{9Gy}}$ (%) | 4.0 ± 2.6        | 3.1 ± 1.6          | 2.2 ± 1.2          | 1.7 ± 0.9          |
| Normal Lung $V_{\text{15Gy}}$ (%) | 7.0 ± 3.6         | 5.9 ± 2.6          | 4.7 ± 2.2          | 3.7 ± 1.7          |
| Normal Lung $V_{\text{40Gy}}$ (%) | 12.8 ± 4.9       | 11.3 ± 3.9         | 9.8 ± 3.5          | 9.4 ± 4.5          |
| Normal Lung $V_{\text{50Gy}}$ (%) | 18.2 ± 5.0        | 17.2 ± 4.2         | 15.6 ± 3.7         | 14.6 ± 3.8         |

PIL: prescription isodose line relative to the maximum dose, GTV: gross target volume, PTV: planning target volume, $D_{\text{mean}}$: mean dose, $D_{98\%}$: PTV mean dose, $D_{95\%}$: PTV prescription isodose line relative to the maximum dose, PIL: percentage isodose line relative to the maximum dose, $D_{\text{xy}}$: target dose conformity index, $nCI$: target dose conformity index. *Significant difference from the reference 85% PIL based on PTV $D_{95\%}$ prescription.
The dose of 3 × 18 Gy at 85% PIL (151 Gy_{10} to PTV D_{95%} and D_{\text{max}} = 198 Gy_{10}) reference dose level in our study) may very likely be reduced to 3 × 14 Gy at 60% PIL (101 Gy_{10} to PTV D_{95%} and D_{\text{max}} = 233 Gy_{10}), resulting in substantial reductions in dose to OARs and even possibly in an increase in tumor control probability (TCP).

Based on this idea, this study further investigated the potential of significant dose de-escalation for SBRT by making best use of the physics derivable from the LED phenomenon. When we prescribed the dose in a way that GTV D_{50%} equals 54 Gy (BED = 151 Gy_{10}) for all PIL with the aim to keep the TCP constant, the resulting BED in the PTV D_{95%} ranged from 71.0 to 79.5 Gy_{10}, and 87.1 to 92.7 Gy_{10} at 60% and 70% PIL, respectively. While such PTV doses may seem low in comparison to previous publications, a recent investigation of PTV prescription dose reduction with constant high GTV mean doses found high local control for lung tumors even with low PTV prescription doses (PTV D_{95%} BED ≥ 89.7 Gy_{10} vs. < 89.7 Gy_{10}, hazard ratio 0.077, confidence interval 0.012–0.503, p = 0.001) [13]. Hence, we may hypothesize that 3 × 18 Gy prescribed to the mean GTV dose at 60 to 70% PIL may still result in high LC (> 90% [13]) while substantially reduce the dose to the lungs and other OARs.

In practice, prescription based on the GTV mean dose can be optimized for different combinations of dose fractionation schedule and PIL. For example, 54 Gy GTV mean dose could be delivered in 4 fractions at 60% PIL, producing PTV D_{95%} of 79.5 Gy_{10} that is roughly equivalent to 48 Gy in 4 fractions prescribed to the isocenter as commonly practiced in Japan [27]. For dose fractionation schedules with more fractions, 54 Gy GTV mean dose could be delivered in 5 fractions, at slightly higher PIL at ~ 67%, producing PTV D_{95%} of 66.2 Gy_{10} equivalent to 50 Gy in 5 fractions reported by Aoki et al. [11]. Alternatively, the prescription can also be re-normalized to higher median GTV dose than 54 Gy to achieve the desired PTV D_{95%} covered by the optimal PIL. Table 3 is provided to predict the 3-year local control rate from different dose schedules and prescription methods reported in the literature and in this study.

Nevertheless, it is worthwhile to note that the concept of GTV-based prescription for lung SBRT and outcomes for such method are exclusively limited to robotic SBRT so far [13, 15], although the data is part of and fits nicely to recent TCP modeling [9, 10]. Clinical implementation of the proposed dose de-escalation approach by optimized PIL at ~ 60% with other techniques such as VMAT must be taken with great caution, and further clinical studies are warranted to validate its efficacy and safety. It is admitted that this study did not fully address the implementation issues of GTV-based prescription. Future studies would be required to develop a link of the GTV prescription with the conventional concept of PTV prescription isodose line, the dose encompassing level of the PTV and their interactions with other patient-dependent / treatment technique-specific factors such as tumor motion range, PTV definition, etc. Further limitations to this study come from the limited number of presented cases as other parameter such as lesion location, volume and dimensions or density of the lesions itself could not have been statistically investigated.

**Conclusions**

Optimizing the Monte Carlo calculated prescription isodose level for VMAT has the obvious advantage of improving the dosimetric quality of lung SBRT treatment plans and offers the possibility to achieve dose de-escalation. Further clinical investigation of gross tumor volume based dose prescription and optimal prescription isodose levels are warranted.

---

**Table 3** Summary of the biological effective dose (BED) to 95% of the planning target volume (PTV D_{95%}) and the 3-year local control (LC) rates in the literature

| Prescription | Isodose level at PTV edge | Dose algorithm | Total dose | BED (Gy_{10}) in 3 fractions | BED (Gy_{10}) in 4 fractions | BED (Gy_{10}) in 5 fractions | 3-years LC |
|--------------|--------------------------|---------------|------------|-----------------------------|-----------------------------|-----------------------------|-----------|
| Aoki et al. [11] | Isocenter | 80% | Type-A | 50 | 66.2 | 95.0% |
| Onishi et al. [12] | Isocenter | 80% | Type-A | 48 | 62.3 | 90.0% |
| Yoshitaki et al. [31] | Isocenter | 80% | Type-A | 48 | 62.3 | 90.0% |
| Shibamoto et al. [32] | Isocenter | 80% | Type-A | 48 | 62.3 | 90.0% |
| Ricardi et al. [33] | PTV edge | 80% | Type-A | 48 | 62.3 | 90.0% |
| Hassbeek et al. [34] | PTV edge | 80% | Type-A | 60 | 145.7 | 89.3% |
| This study | GTV mean dose | 70% | Type-B | 54 | 89.2 | 76.7 | 69.1 |
| | | 60% | Type-B | 74.3 | 64.4 | 58.4 |

Note: BED_{10} (α/β = 10 Gy) was calculated after adjusting the physical prescription dose by a factor of 0.88 for type-A algorithm with respect to type-B Monte Carlo algorithm according to Ref [37].
Abbreviations
3DCT: Three-dimensional computed tomography; 4DCT: Four-dimensional computed tomography; BED: Biological effective dose; DTV: Dose-volume histogram; GTV: Gross target volume; LED: Large electronic disequilibrium; MC: Monte Carlo; MdV: Mid-ventilation; NLCl: Multi-leaf collimator; MLD: Mean lung dose; MU: Monitor units; NSCLC: Non-small cell lung carcinoma, OAR: Organ–at–risks; PB: Pencil beam; PLL: Prescription isodose line; PTV: Planning target volume; SBRT: Stereotactic body radiotherapy; TCP: Tumor control probability; VMAT: Volumetric–modulated arc radiotherapy

Acknowledgements
N/A

Funding
The study did not receive funding.

Availability of data and materials
The data will be made available upon request.

Authors’ contributions
MC designed the study and prepared the manuscript. MW, RL, SC and MC generated the study treatment plans. RL, MC, and OB analyzed the results. MC and OB designed and offered the final proof-read of the data and manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the New Territories West Cluster Clinical and Research Ethics Committee (reference number: NTWC/CREC/15138) and ethics approval was not required.

Consent for publication
N/A

Competing interests
The authors declare that they have no competing interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 University Medical Center Schleswig–Holstein, Campus Kiel, Department for Radiation Oncology, Arnold–Heller–Strasse 3, Haus 50, Karl–Lennert–Krebscrtom Nord, 24105 Kiel, Germany. 2 Imperial College London Healthcare NHS Trust, Department of Radiation Physics, London, UK. 3 Tuen Mun Hospital, Department of Clinical Oncology, Special Administrative Region of China, Hong Kong, Hong Kong, Special Administrative Region of China. 4 Saphir Radiosurgery Center Northern Germany, Güstrow, Germany.

Received: 20 March 2017 Accepted: 29 January 2018

Published online: 09 February 2018

References
1. Disher B, Hajdok G, Gaede S, Mulligan M, Battista J. Forcing lateral electron disequilibrium to spare lung tissue: a novel technique for stereotactic body radiation therapy of lung cancer. Phys Med Biol. 2013;58:6641.
2. Qala J, Kapanen M. Quantification of dose differences between two versions of Acuros XB algorithm compared to Monte Carlo simulations — the effect on clinical patient treatment planning. J Appl Clin Med Phys. 2015;16:213–25.
3. Zheng D, Zhang Q, Liang X, Zhu X, Verma V, Wang S, Zhou S. Effect of the normalized prescription isodose line on the magnitude of Monte Carlo vs. pencil beam target dose differences for lung stereotactic body radiotherapy. J Appl Clin Med Phys. 2016;17:48–59.
4. Oku Y, Takeda A, Kunieda E, Sudo Y, Ooko Y, Aoki Y, Shimouchi Y, Nishina R, Nomura K, Sugiuira M, Ohashi T. Analysis of suitable prescribed isodose line fitting to planning target volume in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Pract Radiat Oncol. 2012;2:46–53.
5. Ding C, Solberg TD, Huychushiuk B, Xing L, Heinzeler J, Timmerman RD. Optimization of normalized prescription isodose selection for stereotactic body radiotherapy: conventional vs robotic linac. Med Phys. 2013;40(3):031705.
6. Takeda A, Ooku Y, Sakuji N, Eriguchi T, Aoki Y, Enomoto T, Kanoke T, Nishima R, Kunieda E. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume. J Radiat Res. 2014;55:988–95.
7. Guckenberger M, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, et al. Safety and efficacy of stereotactic body radiotherapy for stage I non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013;8:1030–8.
8. Bibault J-F, Mirabel X, Lacorniere T, Tesiche E, Reynaert N, Lartigau E. Adapted prescription dose for Monte Carlo algorithm in lung SBRT: clinical outcome on 205 patients. PLoS One. 2015;10:e0133617.
9. Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanka O, Boda-Heggemmann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol. 2016;118:485–91.
10. Klement RJ, Allgäuer M, Andratschke N, Blanka O, Boda-Heggemmann J, Dieckmann K, Duma M, Ernst I, Flentje M, Ganswindt U, et al. Bayesian cure rate modeling of local tumor control: evaluation in stereotactic body radiotherapy for pulmonary metastases. Int J Radiat Oncol Biol Phys. 2016;94:944–951.
11. Aoki M, Hatayama Y, Kawaiuchi H, Hirose K, Sato M, Akimoto H, Fujoka I, Ono S, Tsushima E, Takai Y. Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules. Radiat Oncol. 2016;11:5.
12. Onishi H, Ataki T. Stereotactic body radiotherapy for stage I non-small-cell lung cancer: a historical overview of clinical studies. Jpn J Clin Oncol. 2013;43:345–50.
13. Stora S, Balermpas P, Chan MKH, Huttenlocher S, Wurster S, Keller C, Imhoff D, Rades D, Dunst J, Rödel C, et al. Breathing-motion-compensated robotic guided stereotactic body radiotherapy. Strahlenther Onkol. 2018;194(2):143–55.
14. Suentjens J, Lartigau EF, Cos S, et al. ICRU Report 91. J ICRU. 2014;14(2):NP.
15. Lacomerie T, Libonsa A, Mirabel X, Lartigau E, Reynaert N. GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms. Radiat Oncol. 2014;9:223.
16. Miura H, Masai N, Oh R-J, Shiomi H, Yamada K, Sasaki I, Usmani M, Inoue T. Dosimetric comparison of different prescription modes in lung stereotactic body radiotherapy. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology. 2014;14:14–9.
17. Miura H, Masai N, Oh R-J, Shiomi H, Sasaki J, Inoue T. Approach to dose definition to the gross tumor volume for lung cancer with respiratory tumor motion. J Radiat Res. 2013;54:140–5.
18. Chan MKH, Kwong DLM, Law GML, Tam E, Tong A, Lee V, Ng SCY. Dosimetric evaluation of four-dimensional dose distributions of CyberKnife and volumetric-modulated arc radiotherapy in stereotactic body lung radiotherapy. J Appl Clin Med Phys. 2013;14:336–49.
19. Sonke J-J, Rossi M, Wolthus J, van Herk M, Damen E, Belderbos J. Frameless stereotactic body radiotherapy for lung cancer using four-dimensional cone beam CT guidance. Int J Radiat Oncol Biol Phys. 2009;74:657–74.
20. Hurkmans CW, Cuipers JP, Lagervenfad FJ, Wilder J, van der Heide UA, Schuring D, Senan S. Recommendations for implementing stereotactic radiotherapy in peripheral stage IIA non-small-cell lung cancer: report from the quality assurance working party of the randomised phase III ROSEL study. Radiat Oncol. 2009;4:1.
21. Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, Videtic GM, Bradley J. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small-cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88:1092–9.
22. Xiao Y, Papeiz L, Paulus R, Timmerman R, Straube WL, Bosch WR, Michalski J, Galvin JM. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;73:1235–42.
23. Videtic GM, Hu C, Singh AK, Chang J, Parker W, Oliver KR, Schild SE, Komaki R, Urbanic J, Timmerman RD, Choy H. A randomized phase 2 study
comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015; 93(4):757-64.

24. Fippel M. Fast Monte Carlo dose calculation for photon beams based on the VMC electron algorithm. Med Phys. 1999;26:1466–75.

25. Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans technical note. J Neurosurg. 2000;93:219–22.

26. Jeelani U, Alber M. A finite size pencil beam algorithm for IMRT dose optimization: density corrections. Phys Med Biol. 2007;52:617.

27. Nagata Y, Hiraoaka M, Shibata T, Oishi H, Kokubo M, Karasawa K, Shioyama Y, Ohnmaru R, Kunieda E, Ishikura S. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan clinical oncology group (JCOG0403). Int J Radiat Oncol Biol Phys. 2010;78:22–8.

28. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PAS, Fakiris AJ. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2012;82:457–62.

29. Chang JY, Li Q-Q, Xu Q-Y, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehren R, Swisher SG, Roth JA. Stereotactic ablative radiotherapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”? Int J Radiat Oncol Biol Phys. 2014;88:120–8.

30. Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, Sonke J-J, Bissonnette JP, Wilbert J, Xiao Y, Belderbos J. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012;7:1382–93.

31. Yoshitake T, Nakamura K, Shiyo H, Sasak T, Ohga S, Shinoto M, Terashima K, Araki K, Matsumoto K, Matsu Y, Baba S, Honda H. Stereotactic body radiotherapy for primary lung cancers clinically diagnosed without pathological confirmation: a single-institution experience. Int J Clin Oncol. 2015;20(1):53–8.

32. Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murali T, Takaoka T, Hatton Y, Asai R. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015;10(6):950–4.

33. Ricardi U, Filippi AR, Guerani A, Guglielmi FR, Ciammella P, Franco P, Mantovani C, Borasio P, Scagliotti GV, Ragona R. Stereotactic body radiotherapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer. 2010;68(1):72–77.

34. Haasbeek CJ, Lagenwarde FJ, Cuijpers JP, Slotman BJ, Seran S. Is adaptive treatment planning required for stereotactic radiotherapy of stage I non-small-cell lung cancer? Int J Radiat Oncol Biol Phys. 2007;67(5):1370–4.